Compare CASI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASI | NEUP |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 21.7M |
| IPO Year | 1996 | N/A |
| Metric | CASI | NEUP |
|---|---|---|
| Price | $0.94 | $4.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $21.00 |
| AVG Volume (30 Days) | 49.1K | ★ 51.2K |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,846,000.00 | $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.72 | N/A |
| 52 Week Low | $0.75 | $3.27 |
| 52 Week High | $3.09 | $21.40 |
| Indicator | CASI | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 52.15 |
| Support Level | $0.94 | $3.98 |
| Resistance Level | $1.01 | $4.18 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 30.03 | 65.04 |
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.